×

Elif Yilmaz, M.D.

Elif Yilmaz, M.D.

Harold C. Simmons Comprehensive Cancer Center

Internal Medicine - Hematology/Oncology
Stem Cell Transplantation
Cellular therapies for indolent and aggressive lymphomas

New Patient Appointment Accepting Virtual Visits or 214-645-4673

New Patient Appointment or 214-645-4673

See Dr. Yilmaz's Locations

Biography

Elif Yilmaz, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in indolent and aggressive lymphomas, cellular therapies, and bone marrow transplant.

Dr. Yilmaz earned her medical degree at Istanbul University in Turkey. She completed a residency in internal medicine at Sinai Hospital of Baltimore and gained advanced training in hematology and medical oncology through fellowships at George Washington University and Georgetown University School of Medicine.

Certified by the American Board of Internal Medicine, she joined the UT Southwestern faculty in 2022.

Dr. Yilmaz is a member of the American Society of Hematology and the American Society of Clinical Oncology, among other professional organizations.

She has delivered several presentations and published several academic articles related to her areas of expertise.

Education & Training

Medical School - Cerrahpasa Medical School
Internship - Maimonides Medical Center (2015-2016), Internal Medicine
Residency - Sinai Hospital of Baltimore (2016-2019), Internal Medicine
Fellowship - George Washington University (2019-2021), Hematology Oncology
Fellowship - MedStar Georgetown University Hospital (2021-2022), Hematology Oncology

Professional Associations & Affiliations

American Society for Transplantation and Cellular Therapy
American Society of Clinical Oncology
American Society of Hematology
Society of Hematologic Oncology

Honors & Awards

High Honor Student Award 2013, Educational Committee of Istanbul University Cerrahpasa Faculty of Medicine

Books & Publications

Publications
- A Review on Splenic Diffuse Red Pulp Small B-Cell Lymphoma.
  Yilmaz E, Chhina A, Nava VE, Aggarwal A, Current oncology (Toronto, Ont.) 2021 12 28 6 5148-5154
- Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
  Fakhri B, Yilmaz E, Gao F, Ambinder RF, Jones R, Bartlett NL, Cashen A, Wagner-Johnston N, Leukemia & lymphoma 2021 10 62 10 2408-2415
- Phase 2 Study of Nivolumab in Epstein-BarrVirus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas.
  Yilmaz E, Lakhotia R, Pittaluga S, Muppidi J, Phelan JD, Evans S, Pradhan A, Hillsman A, SteinbergSM, Jaffe ES, Wilson WH, Roschewski M, Melani C Blood 2021
- Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
  Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS, Leukemia 2017 10 31 10 2075-2084
- Direct and immune-mediated cytotoxicity of interleukin-21 contributes to anti-tumor effects in mantle cell lymphoma.
  Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS Blood 2015 Jul

Research

Cellular therapies in the management of lymphoid malignancies
Immunodeficiency-associated lymphoproliferative disorders

Clinical Focus

Stem Cell Transplantation
Cellular therapies for indolent and aggressive lymphomas

Elif Yilmaz, M.D.

Dr. Yilmaz talks about her approach to patient care.

New Patient Appointment Accepting Virtual Visits or 214-645-4673